Skip to content
DataLookout
Menu

TRI-MRNCT07693608

An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 18 words
    • Trial status changed: Enrolling by Invitation → Active, Not Recruiting
    • Secondary endpoints: details revised at 3 of 4 entries
  2. Notable Enrolling by invitation onlyv2 Show 4 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Start date changed from estimate of Aug 1, 2026 to Aug 19, 2026
    • Secondary endpoints revised (4)
    • Site contact updated
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Effect of tirzepatide on self-reported use of stimulants
Timeframe: 32 weeks

Secondary (4)

Changes in body mass index from baseline to the end of the 20-week treatment phase
Feasibility of using tirzepatide in individuals with Stimulant Use Disorder
Changes in High-sensitivity C-reactive protein (hs-CRP) levels from baseline to the end of the 20-week treatment phase
Changes in gastrointestinal symptom severity from baseline until the end of the 20-week treatment phase

Arms and interventions

Tirzepatide ArmExperimental

Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 20-week period in accordance with FDA-prescribing label guidelines.

Drugs: Tirzepatide

Sites

1 site in 1 country

  • UT Southwestern Medical CenterDallas, Texas, United States